Ronald Hunt
Managing Director @ New Leaf Venture Partners
New York, United States
Ronald Hunt is a Series B investor at New Leaf Venture Partners in New York focused on Health Care and Therapeutics. Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on investments in biopharmaceutical companies. Ron was one of the founders of New Leaf following the spin out from the Sprout Group in 2005, and today has nearly 2 decades of venture capital investment experience. Prior to joining Sprout in early 1998, Ron was a consultantwith the pharmaceutical industry practice at Coopers & Lybrand Consulting and then with The Health Care Group (a division of the Interpublic Group of companies). His consulting work spanned 4 years and focused on strategic and operational engagements for clients in the pharmaceutical and medical device industries. Prior to entering the consulting field, Ron held a number of sales and marketing positions for a combined 8 years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Ron is a graduate of The Wharton School (M.B.A.) and Cornell University (B.S.).
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Ronald Hunt invests in
Stages Ronald Hunt invests in
Countries Ronald Hunt invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (50%)
- Therapeutics 3 (50%)
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Medical Device 1 (17%)
Stage
- Series B 2 (33%)
- Series A 1 (17%)
- Series C 1 (17%)
- Series D 1 (17%)
- Post-IPO Equity 1 (17%)
Country
- United States 3 (50%)
- Ireland 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $66M / Series D / Aug 18, 2026 | ||
| Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. | $100M / Post-IPO Equity / Oct 23, 2023 | ||
| Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. | $70M / Series C / Nov 12, 2018 | ||
| Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. | $45M / Series B / May 25, 2017 | ||
| Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives. It aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novelanti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. | $40M / Series A / Mar 24, 2016 | ||
| Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer. | Series B |
Co-Investors
New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, theventure capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.
New Leaf Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Craig Slutzkin
CFO & COO
|
|||
James Niedel
Managing Director
|
|||
Liam Ratcliffe
Managing Director
|
|||
|
Ronald Hunt
Managing Director
|
|||
Vijay Lathi
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ronald Hunt invest in?
Ronald Hunt invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ronald Hunt?
Public channels for Ronald Hunt include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ronald Hunt last invest?
The most recent investment recorded for Ronald Hunt closed in Aug 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
